arrow
M

Michael Crump

Princess Margaret Cancer Centre
H指数:64
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Metabolic tumor volume trajectory during bridging and association with outcomes after CAR T infusion in large B-cell lymphoma

桥接治疗期间大B细胞淋巴瘤的代谢肿瘤体积变化轨迹及其与CAR T输注后结局的关联

2026-11-090
PRE
Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T

桥接疗法在复发/难治性大B细胞淋巴瘤患者接受第三代CAR T治疗中的效果

2026-03-030
PRE
Management and Outcomes for Hodgkin’s Lymphoma Patients with Partial Metabolic Response after First-Line Systemic Therapy

霍奇金淋巴瘤患者在一线全身治疗后的部分代谢缓解期的管理与结局

2026-02-270
PRE
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti–HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial

替诺福韦艾拉酚胺用于预防HBsAg阴性、抗-HBc阳性患者接受利妥昔单抗为基础化疗时HBV再激活:一项多中心随机对照试验

2025-12-030
OAAI
Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

入组时功能状态较差的患者在接受CAR T细胞疗法进行RR-LBCL三线治疗时经历早期治疗失败。

BLOOD
IF23.1
2024-11-050
PRE
Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

现实世界比较:CAR T细胞疗法与历史标准治疗方案在安大略省加拿大治疗复发难治性大B细胞淋巴瘤患者中的医疗成本和资源利用比较:一项成本后果分析

BLOOD
IF23.1
2024-11-050
PRE
A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

加拿大安大略省复发/难治性大B细胞淋巴瘤的真实世界比较:CAR T细胞疗法与历史标准治疗方法的对比

BLOOD
IF23.1
2024-11-050
PRE
Nivolumab plus AVD in Advanced-Stage Classic Hodgkin's Lymphoma
2024-10-172
PRE
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
2023-12-162
OAAI
Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma
2022-09-2610
PRE